Bristol-Myers Squibb Company (BMY) - Stock Report

Informational research — not investment advice.Full disclaimer

Informational research — not investment advice. Generated in part by AI and may contain errors; not a personal recommendation, solicitation, or offer. ReasyPort is not an authorised or regulated investment firm. Market data may be delayed or inaccurate. Capital is at risk and past performance does not guarantee future results — do your own research and consult a licensed adviser.

Full disclaimer
BMY

Bristol-Myers Squibb Company

ReasyPort View: Neutral — Growth Portfolio Cash Proof Required

Summary

Bristol Myers Squibb is a branded-therapy cash engine in transition: mature, high-margin exclusivity assets still fund the dividend and debt reduction, while the investment case depends on whether Opdivo, Eliquis, Reblozyl, Breyanzi, Camzyos, Cobenfy and the pipeline can replace royalty and legacy-product erosion without milestone, restructuring and leverage leakage consuming the FCFE bridge. At $54.00 as of the 18 June 2026 close, BMY sits about 9% above the selected base-case DCF fair value of $49.40 per share. The same framework carries a downside marker of $40.50, about 25% below price, and an upside marker of $83.70, about 55% above price, using a 7.5% WACC and 2.5% terminal growth. That is not a weak-business verdict: the price already discounts a meaningful cash-flow reset, but it needs proof that the Growth Portfolio can become the next durable cash base before the full upside case is earned.

Latest Proof Snapshot

BMY reported fiscal Q1 2026 results on 30 April 2026. Revenue was $11.489bn, up 3% year over year, with Growth Portfolio revenue of $6.2bn up 12% and Legacy Portfolio revenue of $5.3bn down 6%. GAAP diluted EPS was $1.31 versus $1.20, while non-GAAP diluted EPS was $1.58 versus $1.80; both Q1 2026 figures included a $(0.03) net acquired-IPRD/licensing impact from $94m of acquired IPRD charges and $13m of licensing income, separate from total specified items. Management reaffirmed FY 2026 guidance for revenue of about $46.0bn-$47.5bn and non-GAAP diluted EPS of $6.05-$6.35, with both tracking toward the upper end. The cash snapshot is more cautious than the EPS snapshot. Q1 2026 operating cash flow was $1.104bn, capex was $0.347bn and dividends were $1.283bn, so post-capex cash for the quarter of $0.757bn fell $0.526bn short of dividends before any discretionary buyback. That one-quarter gap should not be annualized, but it is the right investment test for 2026: BMY must turn the full-year guidance into cash after R&D, capex, interest and dividends while the high-margin royalty and legacy streams decline.

Key Macro Issue

The key macro issue is not drug-pricing pressure in isolation, but whether Eliquis repricing and legacy royalty erosion pass through net revenue and gross margin faster than the Growth Portfolio can rebuild post-capex cash, dividend coverage and debt-reduction capacity.

Business Overview

What The Company Actually Does

Bristol Myers Squibb discovers, develops, licenses and commercializes prescription medicines, with economics concentrated in patented branded therapies led by biologics and cell therapies but also including small molecules such as Cobenfy, Sotyktu and Camzyos. The company reports one operating segment, so the useful segmentation is economic rather than divisional: Growth Portfolio launches, Eliquis and other legacy cash contributors, royalty streams, and the R&D pipeline that must replace lost exclusivity.

How The Business Is Organized

The portfolio is now split between Growth Portfolio revenue and Legacy Portfolio revenue. In Q1 2026, Growth Portfolio revenue of $6.2bn represented the majority of reported revenue and was driven by therapies such as Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Sotyktu, Krazati and Cobenfy. Legacy Portfolio revenue of $5.3bn still included Eliquis at $4.137bn in Q1 2026, but also mature products under generic pressure, including Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.

What Management Appears To Be Prioritizing

Management is prioritizing a funded portfolio reset rather than balance-sheet expansion. The company is reaffirming FY 2026 revenue and non-GAAP EPS guidance, holding $5.014bn of share repurchase authorization unused under the public program as of 31 March 2026, and emphasizing R&D focus, business development discipline, dividend commitment and investment-grade credit quality. The investment question is whether that discipline produces cash available to shareholders, not simply more pipeline breadth.

🔒

Sign in to read the full report

Create a free account to unlock the rest of this report and access all published research.